Trial Profile
Phase II Efficacy and Safety Study of Dasatinib in Patients With Chronic and Accelerated Phase Chronic Myeloid Leukemia Relapsing After Allogeneic Blood or Bone Marrow Transplantation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 03 May 2011 Planned end date changed from 1 Jun 2014 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 03 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Mar 2010 Actual initiation date (Feb 2010) added as reported by ClinicalTrials.gov.